

Skin Disease-Oriented Team

Clinical Research Treatment Flowchart

Clinical Research Manager:
Mehir Tharani

Clinical Research Coordinators:
Bao-An Huynh
Natalie Arechiga
Erin Palmer-Torrison

Data Coordinators:
Anastasiia Reipolska

Open

Low Accrual

Pending Activation or Suspended

First Line, Resectable

Adjuvant, Stage 2

**First Line, Stage 3
Neoadjuvant + Adjuvant**

**First Line, Metastatic or unresectable
without previous CPI**

SWOG 2015
1cm v 2cm margin
PI: Yamamoto
CRC: N. Arechiga
Accrual: 8/30

UCI 23-220
Pembro vs Biosimilar
PI: Chow
CRC: E. Palmer-Torrison
Accrual: 0/10

EA6194
TLR9 agonist+Pembro + Sx vs
Pembro + Sx
PI: Tran
CRC: E. Palmer-Torrison
Accrual: 3/5

EA6141
(III or IV)
Ipi + Nivo + sargramostin vs. Ipi + Nivo
PI: Chow
CRC: B. Huynh
Accrual: 4/7

UCI 22-42
Neoadjuvant
TransCon Toll like receptor
(TLR) 7/8 agonist
PI: Tewari
Coord: Jiana Ejbara
Accrual: 0/3

UCI 23-220
Adjuvant Pembro vs Biosimilar
PI: Chow
CRC: E. Palmer-Torrison
Accrual: 0/10

UCI 22-101
(III or IV)
Nivo + Rela IV vs SubQ
PI: Chow
CRC: N. Arechiga
Accrual: 4/12

HER2 + /
ERBB2
amp

UCI 20-67

DF1001 (HER2 NK-
engager)
PI: Valerin
CRC: M. Nguyen
Accrual: 18/20

UCI 21-40

*(Locally Advanced or
Metastatic Solid
Tumors)*

DF6002 as a
Monotherapy and
in Combination w/
nivo

PI: Valerin
CRC: B. Huynh
Accrual: 5/6
Waitlist only

**UCI 22-87
(RMC-6236)**

PI: Ou
Mechanism: TKI
Coordinator: O. Quines
Accrual: 14/20
RAS Mutation

UCI 23-197

DF6215 (IL-2)
PI: Valerin
CRC: N. Arechiga
Accrual: 0/5

UCI 22-156

PI: Parajuli
Mechanism: TIL
Coordinator: J. Miranda
Accrual: 0/5

Open

Low Accrual

Pending
Activation
or
Suspended

Non-interventional Trials

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto

CRC: Anastasiia R.

Accrual: 76/90

Open

Low Accrual

Pending
Activation
or
Suspended

Recurrent

ETCTN 10592

M1774 +/- avelumab

PI: Gao

CRC: N. Arechiga

Accrual: 0/6

Open

Low Accrual

Pending
Activation
or
Suspended

First Line

UCI 22-42

TransCon Toll like receptor
(TLR) 7/8 agonist
PI: Tewari
Coord: Jiana Ejbara
Accrual: 0/3

Broad Phase 1 trials

UCI 22-87

(RMC-6236)
Mechanism: TKI
PI: Ou
Coordinator: O. Quines
Accrual: 14/20
RAS Mutation

UCI 21-40

*(Locally Advanced or Metastatic
Solid Tumors)*
DF6002 as a Monotherapy
and in Combination w/ nivo
PI: Valerin
CRC: B. Huynh
Accrual: 5/6
Waitlist only

Open

Low Accrual

Pending
Activation or
Suspended

Non-interventional Trials

UCI 23-153
Topical HT-001 for Skin Toxicities w/EGFR Inhib.
PI: Smith
CRC: B. Huynh
Accrual: 0/6

UCI 11-30
(IRB 2008-6307)
Skin Imaging with Technologies in Development
PI: Kelly
Accrual: 626/750

UCI 13-13
(IRB 2011-8494)
In-Vivo Non-Invasive Skin Imaging Using
Multiphoton Microscopy and Multispectral Imaging
PI: Kelly
Accrual: 202/250